Literature DB >> 16411035

The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension.

S P McKenna1, N Doughty, D M Meads, L C Doward, J Pepke-Zaba.   

Abstract

OBJECTIVE: No outcome measures specific to pulmonary hypertension (PH) currently exist. The aim of the study was to develop health-related quality of life (symptoms and functioning) scales and a quality of life scale that would allow comprehensive, accurate and valid patient-reported outcome assessment in clinical studies.
METHODS: The content of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) was derived from qualitative interviews conducted with 35 patients. Item reduction was based on the analysis of responses to a postal survey (n=75) and patient interviews (n=15) designed to determine face and content validity. A final postal validation study (n=91) was performed to determine reproducibility and construct validity.
RESULTS: The questionnaire was well received by participants who found it to be relevant, comprehensible and quick and easy to complete. Rasch and factor analyses were conducted to ensure unidimensionality of the final CAMPHOR scales; Overall symptoms (made up of Energy, Breathlessness and Mood subscales), Functioning and Quality of life. The CAMPHOR scales had good internal consistency (alpha=0.90-0.92) and reproducibility (test-retest correlations=0.86-0.92). They also exhibited convergent, divergent and known groups validity.
CONCLUSIONS: The CAMPHOR is a valuable new instrument for assessing patient-reported outcome in PH clinical trials and routine practice.

Entities:  

Mesh:

Year:  2006        PMID: 16411035     DOI: 10.1007/s11136-005-3513-4

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  25 in total

1.  The needs-based approach to quality of life assessment.

Authors:  Stephen P McKenna; Lynda C Doward
Journal:  Value Health       Date:  2004 Sep-Oct       Impact factor: 5.725

2.  Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis.

Authors:  L C Doward; A Spoorenberg; S A Cook; D Whalley; P S Helliwell; L J Kay; S P McKenna; A Tennant; D van der Heijde; M A Chamberlain
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

Review 3.  Primary pulmonary hypertension.

Authors:  L J Rubin
Journal:  N Engl J Med       Date:  1997-01-09       Impact factor: 91.245

4.  Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial.

Authors:  Symone B Detmar; Martin J Muller; Jan H Schornagel; Lidwina D V Wever; Neil K Aaronson
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

5.  The QLDS: a scale for the measurement of quality of life in depression.

Authors:  S M Hunt; S P McKenna
Journal:  Health Policy       Date:  1992-10       Impact factor: 2.980

6.  Cutaneous findings in patients with pulmonary arterial hypertension receiving long-term epoprostenol therapy.

Authors:  Sarah A Myers; Gregory S Ahearn; M Angelica Selim; Victor F Tapson
Journal:  J Am Acad Dermatol       Date:  2004-07       Impact factor: 11.527

7.  Cross-cultural development of a quality of life measure for men with erection difficulties.

Authors:  T H Wagner; D L Patrick; S P McKenna; P S Froese
Journal:  Qual Life Res       Date:  1996-08       Impact factor: 4.147

8.  Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials.

Authors:  S P McKenna; S A Cook; D Whalley; L C Doward; H L Richards; C E M Griffiths; D Van Assche
Journal:  Br J Dermatol       Date:  2003-08       Impact factor: 9.302

9.  Psychophysical bases of perceived exertion.

Authors:  G A Borg
Journal:  Med Sci Sports Exerc       Date:  1982       Impact factor: 5.411

10.  Inhaled iloprost for severe pulmonary hypertension.

Authors:  Horst Olschewski; Gerald Simonneau; Nazzareno Galiè; Timothy Higenbottam; Robert Naeije; Lewis J Rubin; Sylvia Nikkho; Rudolf Speich; Marius M Hoeper; Jürgen Behr; Jörg Winkler; Olivier Sitbon; Wladimir Popov; H Ardeschir Ghofrani; Alessandra Manes; David G Kiely; Ralph Ewert; Andreas Meyer; Paul A Corris; Marion Delcroix; Miguel Gomez-Sanchez; Harald Siedentop; Werner Seeger
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245

View more
  78 in total

1.  Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension.

Authors:  H Chen; T De Marco; E A Kobashigawa; P P Katz; V W Chang; P D Blanc
Journal:  Eur Respir J       Date:  2011-01-27       Impact factor: 16.671

Review 2.  Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.

Authors:  Jennifer L Snow; Steven M Kawut
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

Review 3.  Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension.

Authors:  Hubert Chen; Darren B Taichman; Ramona L Doyle
Journal:  Proc Am Thorac Soc       Date:  2008-07-15

4.  Are transcutaneous oxygen and carbon dioxide determinations of value in pulmonary arterial hypertension?

Authors:  Adriano R Tonelli; Laith Alkukhun; Frank Cikach; Mostafa Ahmed; Raed A Dweik
Journal:  Microcirculation       Date:  2015-05       Impact factor: 2.628

5.  Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Authors:  Colm McCabe; Maxine Bennett; Natalie Doughty; Robert MacKenzie Ross; Linda Sharples; Joanna Pepke-Zaba
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

Review 6.  Biomarkers and prognostic indicators in pulmonary arterial hypertension.

Authors:  Carlos Jardim; Rogerio Souza
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

7.  Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics.

Authors:  R James White; Yana Levin; Kathleen Wessman; Antonia Heininger; Karen Frutiger
Journal:  Pulm Circ       Date:  2013-11-18       Impact factor: 3.017

8.  A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.

Authors:  M Gomberg-Maitland; M L Maitland; R J Barst; L Sugeng; S Coslet; T J Perrino; L Bond; M E Lacouture; S L Archer; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  2009-12-09       Impact factor: 6.875

9.  An assessment of the effects of Iyengar yoga practice on the health-related quality of life of patients with chronic respiratory diseases: a pilot study.

Authors:  Maria Jose Santana; Julia S-Parrilla; Judith Mirus; Martha Loadman; Dale C Lien; David Feeny
Journal:  Can Respir J       Date:  2013 Mar-Apr       Impact factor: 2.409

Review 10.  Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian.

Authors:  Donna Coffin; Karine Duval; Simon Martel; John Granton; Marie-Claude Lefebvre; David M Meads; James Twiss; Stephen P McKenna
Journal:  Can Respir J       Date:  2008-03       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.